Medera is a clinical stage company focusing on the development of next-generation therapeutics for difficult-to-treat and incurable diseases. Founded by globally renowned scientists and clinicians, and managed by seasoned business executives, Medera capitalizes on the world’s first human “mini-Heart” Technology and further extends it to include other mini-Organs to form a unique and comprehensive “mini-Life” Platform for revolutionary disease modelling and drug discovery. Using this pioneering technology platform, we have developed one of the world’s largest gene and cell therapeutic pipelines for cardiovascular diseases, including an extensive catalog of therapeutic vectors and a vast network of clinical sites. Three of our clinical trials are expected to enter Phase 2B in 2022/23.
Medera’s pioneering mini-Life Platform drives our discovery and development processes for novel gene and cell therapeutics in areas of cardiac, vascular, pulmonary, hepatic, skeletal muscular and central nervous systems.
Our mini-Heart Technology, ranging from the world’s first engineered human heart muscle cells to heart patches and fluid-ejecting heart chambers, was invented in the early 2000’s. By working with a number of world-renowned scientists, academic institutions and pharma companies, we have been successful in advancing this technology to version 4.0, making it the only self-functioning mini-Heart Technology in the world. Automation and high-content screening are supported by our custom-designed hardware and software, some of which were co-developed with major pharmaceutical companies.
In addition to healthy human heart models for screening toxicity, the mini-Heart Technology can also model diseased hearts for screening efficacy. These disease models include Friedreich’s Ataxia heart patches and mini-Heart chambers that were developed in collaboration with Pfizer Learn more and Heart Failure with preserved Ejection Fraction (HFpEF) heart muscle strips and mini-Heart chambers as an ongoing partnership with AstraZeneca Learn more, among other disease models.
Since 2021, we have engineered additional mini-Organs, including the mini-Gut, mini-Liver, mini-Lungs, mini-Brain and mini-Vasculature, collectively known as the mini-Life Platform. Building on our self-functioning mini-Heart capable of ejecting fluid, our proprietary multi-Organs bioreactor (patent pending) has been designed and engineered to uniquely link the various mini-Organs for simulating the human systems.
Our mini-Life Platform enhances cost- and time-efficiency, as well as improving the efficacy and dosing accuracy in our new drug discovery and development processes. Not only does this platform uniquely allow drug discovery and development to take place all in the context of human organs and systems from the very beginning without testing in patients, but it also simultaneously reduces the use of animals, thereby strengthening our asset portfolio in a sustainable and accelerated manner.
With this enhanced ability, Medera is presently focusing on the cardiac, vascular, pulmonary and skeletal muscular systems but aims to expand the asset (product) pipeline to others, such as the hepatic and central nervous systems. This uniquely allows Medera to offer one of the largest and most comprehensive portfolios of next-generation therapeutics.